Lenalid 25mg

Lenalid ( Lenalidomide) 25 mg has antitumor activity, it is effectively used as an auxiliary therapy after bone marrow transplantation, treatment of myeloma and mantle cell lymphoma. The preparation includes Lenalidomide 25 mg, which has a narrow-molecular action, promotes the early onset of remission and promotes an increase in interleukin-10 production. Also, Lenalid provides cytotoxicity, prevents the formation and growth of tumor cells that could mutate.

Lenalid 25 mg (Lenalidomide) is the leading compound of a new class of immunomodulators (IMiDsSM), which has both immunomodulatory and anti-angiogenic properties.
Clinical effectiveness and safety of Lenalid 25 mg was confirmed by the results of two multicenter randomized phases III trials in which patients with multiple myeloma received Lenalid along with dexamethasone or one dexamethasone as the 2nd line of therapy. For all the efficacy criteria, including the percentage of complete and partial responses, combined therapy with Lenalid 25 mg and dexamethasone was superior to monotherapy with dexamethasone.

Indications:

Treatment of patients with multiple myeloma who received at least one line of therapy (in combination with dexamethasone).

Contraindications:

According to the instructions, Lenalid 25 mg is contraindicated for use:
– pregnant women;
– women breastfeeding;
– children (as there are not enough clinical trials);
– patients with hereditary immunity to lactose, a lack of lactase or a violation of absorption of glucose – galactose, since the capsules Lenalid contains lactose;
– patients with hypersensitivity to Lenalidomide or the other components of the remedy.

Method of application and dosage:

Treatment is carried out only under the supervision of a doctor – chemotherapist. The primary dose of Lenalid admission – 25 mg per day 1 – 28-day course, in the subsequent time the course and the amount of admission can be prescribed only by the attending physician. It is taken orally, once a day, completely, washed down with a small amount of water.

In patients with recurrent or refractory myeloma, Lenalid in combination with dexamethasone is superior to placebo in combination with dexamethasone. The combination of lenalidomide with dexamethasone effectively increases the frequency of remission, increases the time to progression, and the overall survival of patients with recurrent or refractory multiple myeloma.

Immunomodulator Lenalid has a dual mechanism of action, on the one hand directly destroying tumor cells, and on the other – maintaining remission. In addition, it prevents the development of the disease in patients with a slow-moving, low-symptomatic myeloma.